Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash from Financing Activities (2018 - 2026)

10x Genomics' Cash from Financing Activities history spans 8 years, with the latest figure at $2.2 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 50.37% to $2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.8 million, a 37.67% decrease, with the full-year FY2025 number at $6.8 million, down 37.67% from a year prior.
  • Cash from Financing Activities hit $2.2 million in Q4 2025 for 10x Genomics, up from $617000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for TXG hit a ceiling of $16.2 million in Q2 2021 and a floor of -$3.4 million in Q1 2023.
  • Historically, Cash from Financing Activities has averaged $4.1 million across 5 years, with a median of $3.9 million in 2023.
  • Biggest five-year swings in Cash from Financing Activities: crashed 241.25% in 2023 and later soared 295.51% in 2025.
  • Tracing TXG's Cash from Financing Activities over 5 years: stood at $8.9 million in 2021, then crashed by 43.83% to $5.0 million in 2022, then grew by 12.24% to $5.6 million in 2023, then decreased by 19.53% to $4.5 million in 2024, then plummeted by 50.37% to $2.2 million in 2025.
  • Business Quant data shows Cash from Financing Activities for TXG at $2.2 million in Q4 2025, $617000.0 in Q3 2025, and $3.5 million in Q2 2025.